Latest news with #Nucleus
Yahoo
a day ago
- Business
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Business Wire
3 days ago
- Business
- Business Wire
Domo Named a Leader in the 2025 Nucleus Research Analytics Technology Value Matrix
SILICON SLOPES, Utah--(BUSINESS WIRE)--Today Domo (Nasdaq: DOMO) announced it has been named a leader in Nucleus Research's 2025 Business Intelligence (BI) and Analytics Technology Value Matrix for the fifth consecutive year. Nucleus Research recognized Domo for its ability to combine advanced analytics, interactive dashboards, and near real-time visualizations that help to transform data into actionable insights. The firm also noted that Domo's over 1,000 pre-built connectors help to unify data from ERPs, CRMs, and cloud systems. The company's award-winning AI solution, Domo AI, is highlighted for delivering machine learning, natural language processing, predictive analytics, and generative AI capabilities in a unified service. "Our ranking illustrates Domo's ability to link analytics to actionable outcomes such as deciphering data trends, identifying growth opportunities, and optimizing operations.' - Ben Schein, SVP of Product at Domo Share According to Nucleus Research, organizations are navigating a pivotal transition in 2025, as traditional BI remains essential but is now complemented by a surging demand for AI-enabled analytics that automate data preparation, dashboard creation, and narrative generation. The technical barriers that once limited advanced analytics are rapidly dissolving, empowering a broader spectrum of users to become analysts and enabling data professionals to operate as data scientists. The Nucleus Technology Value Matrix is based on platform functionality and useability, the two characteristics that Nucleus has found to indicate a vendor's ability to deliver both initial return on investment (ROI) and maximum value over time. The functionality and usability scores are calculated based on interviews Nucleus analysts conducted with end users as part of their ongoing research and end-user TechAdvisor inquiries. Nucleus Research also touted Domo's consumption-based pricing model for maximizing value, encouraging cross-team collaboration and delivering measurable ROI. 'We're thrilled to be recognized by Nucleus Research as a 'Leader' in the Analytics Value Matrix for the fifth consecutive year. Our ranking illustrates Domo's ability to link analytics to actionable outcomes such as deciphering data trends, identifying growth opportunities, and optimizing operations,' said Ben Schein, SVP of Product at Domo. 'Domo customers recognize the potential of AI-powered analytics in driving operational efficiency, revenue expansion, and profitability, and we enable this by delivering relevant insights critical to adapting to dynamic market conditions and seizing competitive opportunities.' 'Nucleus has once again ranked Domo as a leader in the Analytics Value Matrix due to its ability to equip organizations with sophisticated end-to-end tools that help to create data products, with powerful AI capabilities that directly link analytics to core operations and profitability,' said Alexander Wurm, Principal Analyst at Nucleus Research, Inc. 'Advancements in AI-driven analytics, and integration with emerging data technologies ensure that Domo remains well positioned in a crowded analytics market.' For a complimentary copy of the 2025 Nucleus Research Value Matrix for Analytics Technology, visit here. About Nucleus Research Nucleus Research is the recognized global leader in investigative ROI technology research. Using a case-based approach, we provide research streams and advisory services that allow vendors and end users to quantify and maximize the return from their technology investments. We deliver the numbers that drive better business decisions. For more information, visit or follow our latest updates on LinkedIn. About Domo Domo is an AI and Data Products platform that helps companies of all sizes leverage data and AI to drive value in today's data-driven world. Built around our customers' preferred data foundation, powered by our award-winning solution, and enriched with our partner ecosystem, the Domo platform enables users to prepare, visualize, automate, distribute, and build end-to-end data products that provide solutions across the entire data journey. From hydrating your data foundation, to building fully embedded applications that can be shared with your employees and customers, to deploying AI models across a variety of providers, Domo gives users the ability to build data products that generate measurable value for the business. For more information, visit You can also follow Domo on LinkedIn, X, and Facebook. Domo is a registered trademark of Domo, Inc.
Yahoo
3 days ago
- Health
- Yahoo
The Gattaca Future Is Here
Advances in the world of embryonic screening: The company Nucleus Genomics announced the launch of Nucleus Embryo yesterday, which they bill as "the first genetic optimization software that lets parents pursuing IVF [in vitro fertilization] see and understand the complete genetic profile of each of their embryos." It's a dashboard, essentially, that lets parents see the full analysis of their frozen embryos—each embryo's probability of having some 900 diseases, as well as information about their appearance (male pattern baldness, eye color, hair color), IQ, and more. You can now compare each embryo to the others, and rank order your preferences for which ones you implant, if you so choose. You can know which embryos are more likely to have seasonal allergies, asthma, restless leg syndrome, schizophrenia, cystic fibrosis, alcoholism, celiac disease, and more. "Some people don't think you should have access to the choice Nucleus Embryo empowers you to make," writes Nucleus CEO Kian Sadeghi. "Here's the thing. It's not their choice to make. It's yours." (For the price of $6,000, of course.) Competitors like Orchid offer essentially the same thing. What's discussed a bit less in all the marketing copy is that you're not genetically tweaking the embryos, you're just discarding the ones that don't meet your specifications. And, look, I don't mean to let my Catholic show too much, but I have a hard time getting excited about a Gattaca future—as do many others who've been following the developments in the world of embryonic screening: Other folks within Silicon Valley are bullish on this, and interested in investing in gene-editing technology, applying it to embryos specifically. So expect this to be something we hear a lot more about in the future: Some people surely believe this is a means to reduce suffering, and that it is better to eliminate embryos that would be possibly destined for great suffering than to allow them to continue to grow and develop into children, and then adults, who would incur extreme hardship (like a life with cystic fibrosis or Tay-Sachs disease). To me, this argument is less compelling, because I don't believe it is the parent's role to pick and choose which children are "desirable" and to discard those with traits that might lead to suffering. I also fear the use of this technology as a means of indulging parental hubris, a belief that you are responsible not just for your child's care and safekeeping and spiritual growth—no matter what is thrown their way—but that you may also craft them into perfect beings who become as attractive as can be, as smart as can be. To some degree, parents do this once the children are outside the womb—they provide them with the best opportunities to grow and learn and foster their natural talents—but I do wonder how it might psychologically alter a child to know that they were selected for life due to their potential for excellence vs. their innate value. But, honestly, my own personal beliefs on this are beside the point. Many libertarians probably disagree with me, and see this technology as a massive expansion of human choice applied to the most important realm. This future is here; public support for IVF is already extremely high, and genetic screening is already routine in pregnancy. It's not crazy to theorize that, as the price tag continues to drop as the marketplace becomes more crowded, this type of screening will catch on for those who use IVF, and that some people—perhaps the most type-A parents with the most disposable income—will even be spurred to choose IVF creation of babies vs. the good old-fashioned method, as it gives them greater control over outcomes (but, if we're being honest, less fun). In other words, we're a far cry from parents trying to optimize their kids' intellect by letting them watch Baby Mozart; techniques for optimization are much more sophisticated now, and a whole bunch of ethical quandaries will come along with that. Expect progressives to object to a society increasingly bifurcated based on ability, corresponding to the disposable income of one's parents, and expect conservatives to object on pro-life grounds. Though, interestingly, maybe the MAGA types—who voted for "the fertilization president" (an image I still hope to get out of my head)—and the Silicon Valley types who are broadly supportive of this technology will sort of join forces with IVF-approving normies and it will all become broadly accepted. It's hard to say how it all plays politically. Another Trump travel ban: On Wednesday, President Donald Trump banned citizens of 12 countries—Afghanistan, Myanmar, Chad, the Republic of Congo, Equatorial Guinea, Eritrea, Haiti, Iran, Libya, Somalia, Sudan, and Yemen—from entering the United States. He also announced restrictions on travel for citizens of Burundi, Cuba, Laos, Sierra Leone, Togo, Turkmenistan, and Venezuela, but stopped short of a full ban. People from those countries will not be allowed to come to the United States permanently or get tourist or student visas, but will be allowed to enter under certain circumstances. This is more extensive than the so-called Muslim travel ban of his first term, and it's not totally clear what the specific reasoning is for barring citizens of these countries from visiting or living in the United States. The attack on Jews in Boulder, Colorado, by an Egyptian man who had overstayed his visa and was thus here illegally, "underscored the extreme dangers" posed by the entry of foreigners, said Trump. Oddly, though, he didn't announce any restrictions on travel by Egyptians. I don't believe this statistic is correct, and I am also very curious about where all our taxpayer dollars are going if they're not going to food assistance for poor kids. Articles like this one claim that "an estimated 1 in 4 children don't have enough to eat—a 46% increase over pre-pandemic numbers" and cite the nonprofit Feeding America. When I follow the link, there's nothing to substantiate this number, and this X user is roughly correct that a huge chunk—some estimates say more like 43 percent—of NYC elementary schoolers are overweight. "Many today insist that it is critical—even morally required—that we use the word 'genocide' to describe Israel's war in Gaza. No other term will do. Those not joining the chorus are allegedly complicit in genocide. Those questioning the nature of the accusation are labeled genocide deniers," write Norman J.W. Goda and Jeffrey Herf for The Washington Post. "Why this insistence? Efforts to delegitimize Israel as colonial and racist began before the state was declared in 1948. Genocide, meanwhile, is the crime of crimes; a state committing genocide is forever illegitimate. Given this history and gravity, we should pose some questions. Israel's war against Hamas in the urban environments of Gaza has led to thousands of civilian casualties. But is genocide really the correct way to describe the war?" "Yunqing Jian, 33, and Zunyong Liu, 34, citizens of the People's Republic of China, were charged in a criminal complaint with conspiracy, smuggling goods into the United States, false statements, and visa fraud, announced United States Attorney Jerome F. Gorgon, Jr.," per a press release from the U.S. Attorney's Office for the Eastern District of Michigan. "The FBI arrested Jian in connection with allegations related to Jian's and Liu's smuggling into America a fungus called Fusarium graminearum, which scientific literature classifies as a potential agroterrorism weapon. This noxious fungus causes 'head blight,' a disease of wheat, barley, maize, and rice, and is responsible for billions of dollars in economic losses worldwide each year. Fusarium graminearum's toxins cause vomiting, liver damage, and reproductive defects in humans and livestock." But it sounds like the scientists mostly failed to file the proper paperwork; will be interesting to see what more comes out about this case. Classic Trump administration: Hell yeah, New Jersey! With age, I conquer my animus and grow in respect for that scrappy little state: The post The Gattaca Future Is Here appeared first on
Yahoo
4 days ago
- Business
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Yahoo
14-05-2025
- Business
- Yahoo
Mustang Energy Corp. Acquires Nucleus Uranium Ltd.
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Mustang Energy Corp. (CSE: MEC, OTC:MECPF, FRA:92T) (the 'Company' or 'Mustang') is pleased to announce that it has completed the acquisition of Nucleus Uranium Ltd. ('Nucleus'), an arm's length British Columbia-based uranium company, pursuant to a share exchange agreement dated May 5, 2025 (the 'Agreement') among the Company, Nucleus, and Golden Mile Resources Corp. (the 'Shareholder'), the former sole shareholder of Nucleus. Nucleus, now a wholly-owned subsidiary of the Company, is the sole registered and beneficial owner of the Nucleus Saskatchewan project, which consists of six mineral claims covering approximately 18,571 hectares in the Athabasca Basin, Saskatchewan (the 'Nucleus Project'). Pursuant to the Agreement, the Company acquired all of the outstanding common shares in the capital of Nucleus from the Shareholder in consideration for the issuance of an aggregate of 9,000,000 common shares (each, a 'Consideration Share') in the capital of the Company at a deemed price of $0.26 per Consideration Share to certain designees of the Shareholder, in addition to paying certain transaction related expenses of the Shareholder. About Mustang Energy Corp.: Mustang is a resource exploration company focused on acquiring and developing high-potential uranium and critical mineral assets. The Company is actively exploring its properties in Northern Saskatchewan, Canada and holds 92,211 hectares in around the Athabasca Basin. Mustang's Ford Lake project covers 7,743 hectares in the prolific eastern Athabasca Basin, while its Cigar Lake East and Roughrider South projects span 3,442 hectares, and the south-east region with the Spur Project (17,929 hectares). Mustang has also established a footprint in the Cluff Lake region of the Athabasca Basin with the Yellowstone Project (21,820 hectares) and further expanded its presence in the south-central region of the Athabasca Basin with the Dutton Project (7,633 hectares). For further information, please contact: Mustang Energy Corp. Attention: Nicholas Luksha, CEO and DirectorPhone: (604) 838-0184This news release contains certain 'forward-looking statements' within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as 'anticipates', 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed', 'positioned' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. These statements include but are not limited to the prospective nature of the Company's mineral properties, now including the Nucleus Property, for uranium. Various assumptions were used in drawing the conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management of the Company and Nucleus at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company and Nucleus are under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
